• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Should we start getting worried?





















































OK, this is the scoop.

The FDA is not giving us the abuse label we need to be on par with Purdue.
Additional studies will be needed (and they have to get better results) if we want to move forward.
Accepting the approval now would be a launch disaster.
 




it's a shitty migraine patch, in a crowded migraine market, and another tamper resistant hydrocodone product , which Is 1 of 4 coming to market over the next several months, crowded too can you say? What's with the anticipation of selling these two drugs? Might as well get a job selling a statin or a ppi. Also I'm not sure everyone understands that this is not a specialty role , it's a hybrid that has at least 40% primary care call targets.... If the hiring manager tells you any different , he is LYING.. Trust me I know, my friend is a DM with the division ...
 




OK, this is the scoop.

The FDA is not giving us the abuse label we need to be on par with Purdue.
Additional studies will be needed (and they have to get better results) if we want to move forward.
Accepting the approval now would be a launch disaster.
So, no job for all that were just offered last month and got the update last week.
 




OK, this is the scoop.

The FDA is not giving us the abuse label we need to be on par with Purdue.
Additional studies will be needed (and they have to get better results) if we want to move forward.
Accepting the approval now would be a launch disaster.

This is never going to happen I just withdrew my offer letter and took another gig, good luck to everyone.
 




OK, this is the scoop.

The FDA is not giving us the abuse label we need to be on par with Purdue.
Additional studies will be needed (and they have to get better results) if we want to move forward.
Accepting the approval now would be a launch disaster.



Purdue is paying off the FDA so it doesn't happen!